# Clinical Outcomes

AdventHealth North Pinellas, FL

96%
DECREASE
in MRSA bacteremia
hospital-wide

Introduced universal nasal decolonization with Nozin for all inpatients in place of screening and contact precautions for MRSA colonized patients. Pre-op nasal decolonization for all surgical patients. Reduced incidence of all-cause SSI for all surgical procedures (from 3/4,313 to 0/4,872 procedures). Saved \$104k.

Arden S. Op Forum Infect. Dis. 2019. 6(S2), S268

2 MO.

#### Frederick Health, MD

51% REDUCTION in S aureus SSI replacing PVP-I

Introduced hospital-wide universal nasal decolonization for all inpatients. Replaced pre-op povidone iodine with Nozin pre- and post-op. Maintained 96% compliance rate. Reduced use of contact precautions. Saved \$223k.

Landis-Bogus K and Belani A. Am. J. Infect. Control. 2019. 47(S6), S39

17 MO.

# AdventHealth Wesley Chapel, FL

98% REDUCTION in total hip SSI Introduced universal nasal and body decolonization for all high-risk patients, replacing targeted screening and contact precautions. Nozin pre- and post-op decolonization replaced screening and decolonization with mupirocin for all orthopedic surgical patients. Maintained rate of zero SSI in total knee replacement. Reduced use of contact precautions. Saved \$200k.

Stegmeier H. Op Forum Infect. Dis. 2019. 6(S2), S446

12 MO.





Nozin® NOVA<sup>SM</sup> programs utilize a proven approach to help reduce the risk of infections, to improve care and to lower costs. These programs include the use of Nozin® Nasal Sanitizer® antiseptic and are supported by the independent clinical studies cited below.

#### AdventHealth Tampa, FL

\$1.4m

Introduced universal nasal decolonization with Nozin for all inpatients, replacing targeted screening, isolation, and decolonization with mupirocin for MRSA colonized patients. Retained low MRSA bacteremia rate and reduced contact precautions. Saved \$1.4m.

Whitaker J. Op Forum Infect. Dis. 2019. 6(S2), S25

12 MO.

#### Jackson North Medical Center, FL

74% DECLINE in MRSA bacteremia Compared to screen and isolate in the ICU only, a hospital-wide universal decolonization bundle reduced bacteremia by 74%.
Significant decrease in the SIR after the introduction of Nozin.

Jimenez A et al. Op Forum Infect. Dis. 2019. 6(S2), S268

30 MO.

# Methodist University Hospital, TN

100% REDUCTION in MRSA bacteremia Introduced universal nasal decolonization with Nozin in a tertiary-care adult intensive care setting, reduced MRSA bacteremia by 100% during study period from baseline rate of 0.2404 to 0. Found that this approach may be a safe and effective alternative to nasal antibiotic that avoids antibiotic resistance risks.

Reeves L et al. Infect Control Hosp Epidemiol. 2020. 41(S1)

7 MO.

#### Universal Health Services Inc., PA

88%
DECREASE
in isolation days

Safely replaced contact precautions (CP) for high-risk MRSA-colonized patients with targeted nasal and body decolonization, leading to significant cost savings and staff satisfaction without any increase in MRSA transmission.

Christie J et al. Am. J. Infect. Control. 2020. 48(8), 922-924

#### Marshall Medical Center, CA

\$64k
SAVINGS
Maintaining
low MRSA rates

Introduced daily nasal decolonization with Nozin to MRSA patients (history, colonized or active). Reduced use of contact precautions. Maintained low MRSA infection rates throughout the study.

Deatherage N. Am. J. Infect. Control. 2016. 44(S6), S101-S102

12 MO.

#### Northwest Healthcare, AZ

64%
REDUCTION
in spine fusion SSI

Replaced nasal povidone iodine with Nozin, paired with existing preoperative CHG bathing, for all spine fusion and laminectomy patients. Reduced spine fusion SSI by 64% and laminectomy SSI by 100%. Estimated cost avoidance of \$164,000 associated with infections prevented.

Candray K. Open Forum Infect Dis. 2020. 7(S1), S479

3 MO.

#### Riverside University Health Medical Center, CA

63%
REDUCTION
AULTRIANCE SEL

Universal preoperative decolonization protocol replaced povidone iodine-based nasal antiseptic with Nozin, paired with preoperative existing CHG bathing. Results include a 63% reduction of all-cause SSI and S589,420 cost-savings from infections prevented.

Gnass S. Open Forum Infect Dis. 2020. 7(S1), S479

6 MO.

#### Bayfront Health Seven Rivers, FL

59% REDUCTION all-cause SSI

Introduced universal nasal decolonization for all preoperative patients added to existing CHG bathing protocol. Reduced all-cause SSI by 59% from average monthly baseline rate of 0.61 to 0.25. Represents an estimated cost avoidance of \$457k. 86% of hospital staff reported increased satisfaction.

Cernich C. Am J Infect Control. 2020. 48(S8), S50

6 MO.

# Baylor Scott & White Orthopedic and Spine Hospital – Arlington, TX

81%
REDUCTION
in Saureus SSI

Introduced a comprehensive nasal decolonization program with Nozin for spine surgery patients, combined with existing CHG bathing protocol. Achieved reduction in S aureus SSI in spine surgery from 1.76 to 0.33 per 100 surgeries.

Mullen A et al. Am J Infect Control. 2017. 45(5), 554-556

15 MO.

### WV University School of Medicine, WV

79% REDUCTION in SSI

Introduced pre- and post-op nasal decolonization with Nozin for total joint arthroplasty patients.

Bostian P et al. Poster presented at American Association of Orthopedic Surgeons (AAOS) Annual Conference. 2018.

7 MO.

# Wellstar Cobb Hospital, GA

100% REDUCTION in total hip and total knee SSI Added nasal decolonization with Nozin to existing preoperative CHG bath for total hip and knee replacement surgeries. Nasal decolonization continued post-op for length of stay. Reduced total hip SSI rate from 0.91 to 0.00 and total knee SSI from 0.36 to 0.00 per 100 procedures. \$400K avoided annually, associated with joint SSI prevention.

Franklin S. Am. J. Infect. Control. 2020. 48(12), 1501-1503

12 MO.

# Medical University of SC Hospital, SC

99%
REDUCTION
in S aureus
nasal carriage

Nasal application of Nozin was effective in reducing S aureus and total bacterial carriage, suggesting the usefulness of this approach as a safe, effective, and convenient alternative to antibiotic treatment.

Steed L et al. Am. J. Infect. Control. 2014. 42(8), 841-846

12hr PERSISTENCE

In Vitro study demonstrates twelve-hour efficacy.

nozin com/in-vitro



Scan for references & more at nozin.com/clinical-outcomes/



©2021 Global Life Technologies Corp. All rights reserved. Made in USA. Outcomes reported by actual users. Your results may vary. Nozin® Nasal Sanitizer® antiseptic is for nasal decolonization. Nozin®, Nozin®, Nova and Nozaseptin® are trademarks of Global Life Technologies Corp. Nozin® Nasal Sanitizer® antiseptic is an OTC topical drug, No claim is made that it has an effect on any specific disease, Patent nos.: nozin.com/patents. 1CCO0630